Regeneron Pharmaceuticals, Inc. (REGN) reported earnings per share (EPS) of $11.56, which beat the Zacks Consensus Estimate of $10.57. The company recorded an EPS of $10.24 in the year-ago period.The upside in the bottom line can be attributed to higher revenues.Total revenues increased 12% year over year to $3.54 billion, fueled by higher Dupixent, Eylea HD and Libtayo sales. Revenues also beat the Zacks Consensus Estimate of $3.38 billion. Shares are trading up in response to the better-than-expected resu ...